Goldman Sachs Group Inc. boosted its stake in shares of Zynex Inc. (OTCMKTS:ZYXI) by 305.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 42,619 shares of the company’s stock after acquiring an additional 32,095 shares during the period. Goldman Sachs Group Inc. owned 0.12% of Zynex worth $1,060,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of ZYXI. Macquarie Group Ltd. bought a new stake in Zynex during the 2nd quarter valued at about $30,000. Rockefeller Capital Management L.P. purchased a new position in Zynex during the 2nd quarter valued at about $37,000. Winslow Evans & Crocker Inc. purchased a new position in Zynex during the 2nd quarter valued at about $107,000. Citigroup Inc. increased its position in Zynex by 38.3% during the 1st quarter. Citigroup Inc. now owns 4,383 shares of the company’s stock valued at $48,000 after purchasing an additional 1,213 shares during the period. Finally, Strs Ohio increased its position in Zynex by 84.6% during the 2nd quarter. Strs Ohio now owns 4,800 shares of the company’s stock valued at $119,000 after purchasing an additional 2,200 shares during the period. 0.05% of the stock is owned by institutional investors.

A number of research analysts have commented on ZYXI shares. HC Wainwright raised shares of Zynex from a “neutral” rating to a “buy” rating and set a $25.00 target price on the stock in a research report on Monday, September 14th. Piper Sandler initiated coverage on shares of Zynex in a research report on Monday, July 20th. They issued an “overweight” rating and a $30.00 price objective on the stock. B. Riley raised shares of Zynex from a “neutral” rating to a “buy” rating and set a $28.00 price objective on the stock in a research report on Wednesday, July 29th. Northland Securities raised shares of Zynex from a “market perform” rating to an “outperform” rating and set a $22.50 price objective on the stock in a research report on Wednesday, September 9th. Finally, Zacks Investment Research raised shares of Zynex from a “sell” rating to a “hold” rating in a research report on Wednesday, September 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.50.

Shares of OTCMKTS ZYXI opened at $16.70 on Monday. Zynex Inc. has a 12 month low of $7.51 and a 12 month high of $29.73. The company has a 50 day simple moving average of $16.07 and a two-hundred day simple moving average of $17.56. The stock has a market cap of $579.59 million, a price-to-earnings ratio of 75.91 and a beta of 1.05.

Zynex (OTCMKTS:ZYXI) last posted its earnings results on Tuesday, July 28th. The company reported $0.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.09. The firm had revenue of $19.26 million during the quarter, compared to analysts’ expectations of $19.12 million. Zynex had a net margin of 33.33% and a return on equity of 152.81%. Sell-side analysts forecast that Zynex Inc. will post 0.28 earnings per share for the current fiscal year.

In other Zynex news, CFO Daniel J. Moorhead bought 2,733 shares of Zynex stock in a transaction on Thursday, July 30th. The stock was bought at an average price of $18.11 per share, with a total value of $49,494.63. Following the completion of the acquisition, the chief financial officer now owns 19,001 shares in the company, valued at $344,108.11. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Thomas Sandgaard sold 1,250,000 shares of the firm’s stock in a transaction on Tuesday, July 14th. The shares were sold at an average price of $22.00, for a total value of $27,500,000.00. The disclosure for this sale can be found here.

About Zynex

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

Further Reading: Options Trading – What is a Straddle?

Want to see what other hedge funds are holding ZYXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zynex Inc. (OTCMKTS:ZYXI).

Institutional Ownership by Quarter for Zynex (OTCMKTS:ZYXI)

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.